Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewNew and emerging disease modifying therapies for multiple sclerosisN-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune EncephalomyelitisMultiple Sclerosis: Where Will We Be in 2020?Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachFingolimod for relapsing-remitting multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisPharmacological treatment for memory disorder in multiple sclerosisFingolimod for relapsing remitting multiple sclerosisOral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineThe role of sphingosine-1-phosphate transporter Spns2 in immune system functionAtacicept: targeting B cells in multiple sclerosisThe emerging role of FTY720 (Fingolimod) in cancer treatmentProtein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaFingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsFingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisOptimizing treatment success in multiple sclerosisThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisImportance of Apolipoprotein A-I in Multiple SclerosisDisease-modifying treatments for multiple sclerosis - a review of approved medicationsOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisNewer therapies for multiple sclerosisStratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupNovel Insights and Therapeutics in Multiple SclerosisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Sphingosine 1-phosphate receptor modulators in multiple sclerosisAlemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionMultiple sclerosis-a quiet revolutionThe human plasma lipidomeAlemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useStage-specific immune dysregulation in multiple sclerosisSphingosine 1-phosphate signallingLysophospholipids and their receptors in the central nervous systemBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewPharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
P2860
Q22241795-5E912D0A-C0C2-42F9-8A0A-7747C5BC4C16Q22242305-BCE8545B-FC9E-4E97-BA5C-D06E051BA148Q22248070-C79EDFA2-64A4-4E58-A4CF-763CDDF687A3Q22252863-040E509B-A4D3-4C29-8DC7-B34B7B00A2BFQ22305854-356928C2-0B96-4E72-8769-A6ECC53EDFD5Q24185882-19ADA52D-6FCD-4840-8EAA-C7F4937EF67AQ24187126-75EA53C5-45A1-475F-AB3E-97EC64C8A5DBQ24201735-81BCD4F0-AC6A-46C5-BE16-05F76541BF7FQ24236597-0A5EB3E3-8C78-4988-8BD6-868E57CAF156Q24564715-9A514425-5A3C-4012-9308-D7C0EFEB53BBQ24597369-9B6FD7EF-4AD6-4DDD-8E3B-FCF0CA157A93Q24599540-F25AD102-478A-457C-9BC6-14F005E5B0C0Q24628925-1F1E00E2-65A8-4A59-AAA9-219D2EBDCBE0Q26748927-E7A5F6A8-F393-42C3-B55D-A63022BB629EQ26752430-29003171-6BFE-4CD6-AF5A-51AF5DA01E41Q26752466-7D62A1BB-8E54-45BA-9E5D-5D16D816CBA8Q26752859-DB2B2C6E-5891-45C5-BE44-9599CCFE9C80Q26765300-47B216AD-D31D-48F1-8FBF-F4B0B8505F8BQ26770664-2C78F513-D891-4FBD-BD29-78A22D03B63CQ26771635-E36ABA26-DA11-4F4D-8E04-39F2F0F5846CQ26771968-6815981E-F491-4E07-A62A-34796F1AFB30Q26773978-CD2C1393-4A7A-4ECB-AFF6-B4C9E7920151Q26774792-E4076E2F-8546-4CB3-8EDB-94D07966D366Q26777329-A7D30AAB-7A46-48C5-9489-67D531615E40Q26777686-63CA1715-A432-464C-A3F5-D1C81800D31CQ26779900-CB9B6AA3-E4A0-4001-ABBE-E4496DBDD374Q26780412-F7B9B40C-EE01-45FF-BC1C-7E30DFFA7600Q26784619-1758E0FE-FAB7-4B5D-ABB2-A0C2522B276AQ26798434-921991EE-4F39-421D-9BE0-8DB04D681DD6Q26799440-52CDD7F1-2059-45E8-AC32-4DFB03982EE4Q26800128-CBC8D1C2-2C0B-455E-9033-954380876A6CQ26822611-358B49C1-0F05-4553-90E7-C428FA8602C4Q26826930-B5024CAB-6A07-432B-94AE-470A2EEEDC37Q26830940-11473E5F-080D-48C1-A679-0DFA2320F405Q26849781-1909CB84-B603-4BCB-999D-40987F2DF95BQ26852859-934C4F6A-520F-42B4-ABC3-F91540418DA6Q26852942-D61136FE-5292-440B-85D7-382363CEE180Q26859168-0664FE64-0CAD-417C-95DD-DC83CC87A98DQ26999417-8690F052-D6B5-4D9E-94A8-63A8E7380CACQ27000269-F0A47828-7A58-46E8-B4F9-99893E2C2431
P2860
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@ast
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@en
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@nl
type
label
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@ast
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@en
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@nl
prefLabel
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@ast
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@en
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@nl
P2093
P50
P3181
P356
P1476
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
@en
P2093
Ana de Vera
Bhupendra O Khatri
Guillermo Izquierdo
Jean Pelletier
Jeffrey A Cohen
Klaus Tiel-Wilck
Paolo Gallo
Ruggero Capra
Shreeram Aradhye
P304
P3181
P356
10.1056/NEJMOA0907839
P407
P577
2010-02-04T00:00:00Z